Navigation Links
HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
Date:5/6/2011

FRAMINGHAM, Mass., and SYDNEY, May 6, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Bank of America Merrill Lynch Health Care Conference at 10:40 a.m. Pacific Time (1:40 p.m. ET) on Tuesday, May 10, 2011.  The conference is being held May 10-12, 2011 at the Encore at Wynn in Las Vegas.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time until May 27, 2011.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
2. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
3. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
4. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
5. HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
6. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
7. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
8. HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
10. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
11. HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology:
(Date:7/24/2017)... SANTA CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... government and financial organizations, today announced it has partnered with WALLIX to ... NIST Special Publication 800-171 . , There are a number of ways to address ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they ... would a pharmacist using that same scale to dispense medication. The first example is ... These illustrations show why it is important to have the right balance for the ...
(Date:7/24/2017)... ... 24, 2017 , ... A Southern California-based author has released a new book ... she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights ... risen above. , In “Memories,” readers get a firsthand look at what Michelle has ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... how to change manufacturers future. , The agency is hammering out a game ... one of the farthest-ranging laws ever to affect FDA-regulated firms. The new law:, ...
(Date:7/24/2017)... ... 24, 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir ... of published author, Ed Clark. Ed Clark is a church music director and ... a minister of music and worship leader for over fifty years. He has ...
Breaking Medicine News(10 mins):